AbbVie Inc (ABBV NYSE) stock market data APIs
$216.3228
2.97(1.4%)
as of September 15, 2025
Try our APIs with
free plan!
AbbVie Inc Financial Data Overview
Price chart is built with
Anychart
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Prev. Close
216.3228
Open
219.2929
High
219.2929
Low
214.7292
52 wk Range
159.4168-221.77
Market Cap
385 709 M
P/E Ratio
104.1196
Shares Outstanding
1 767 M
Revenue
58 328 M
EPS
2.97
Dividends (Yield)
0.0296
Beta
0.525
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with AbbVie Inc (top by weight)
Ticker
100-day Price Change
Weight
HDLB.US
ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B
1.94
(13.42%)
9.80
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AbbVie Inc data using free add-ons & libraries
Get AbbVie Inc Fundamental Data
AbbVie Inc Fundamental data includes:
- Net Revenue: 58 328 M
- EBITDA: 28 074 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-31
- EPS/Forecast: 2.91
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AbbVie Inc News
New
Is ABBV Stock a Buy, Hold, or Sell After Its Almost 23% Rise YTD?
AbbVie ABBV has gained 22.5% so far this year against a decrease of 0.1% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. ABBV Stock Out...
AbbVie (ABBV)’s Dividend Track Record: How It Became a Leader in Consistent Dividends
AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Consistent Dividend Stocks to Buy Now.AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends AbbVie Inc. (NYSE:ABB...
ABBV Quantitative Stock Analysis
Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha...
Assessing AbbVie After Neuro Pipeline Expansion and Double Digit 2025 Share Gains
If you have been watching AbbVie lately and wondering whether now is the right time to buy, sell, or simply hold on, you are definitely not alone. The stock has notched an impressive 21.3% gain year-t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
